Form 4: Exact Sciences EVP Brian Baranick Sells Shares Under 10b5-1 Plan

Brian Baranick, EVP and GM of Precision Oncology at Exact Sciences, sold 929 shares of common stock at $70 per share on October 8, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 8, 2024, Brian Baranick, EVP, GM, Precision Oncology at Exact Sciences Corp, sold 929 shares of common stock at a price of $70 per share.
• The sale was executed under a Rule 10b5-1 trading plan established on May 24, 2023.
• Following the transaction, Baranick directly owns 12,758 shares of common stock.
• Baranick also indirectly owns 454 shares held in a 401(k) plan.
• In addition to the reported shares, Baranick holds 65,007 vested and unvested options and restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an executive's stock sale under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units, aligning executive interests with shareholder value.
• Sales under 10b5-1 plans are a standard practice among public company executives to avoid accusations of insider trading.
• Comparing Baranick's holdings and transactions to those of executives at similar companies like Guardant Health or Foundation Medicine would provide further context.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the pre-planned nature of the transaction mitigates concerns about insider trading.

Key Dates